What are the do’s and don’ts when approaching employers for DTx reimbursement? Join HealthXL in this meeting to share and learn from others’ experiences.
We have seen a significant number of employers starting to incorporate DTx products into their benefits plans (such as Pear Therapeutics reSET, Freespira, etc). Why is this a good route to market for DTx companies? How do we build meaningful and sustainable partnerships with employers? In this session we will discuss:
What products are a good fit for employer partnerships and why? E.g oncology might be less aligned with the employer-focused route to market compared to musculoskeletal pain management or other areas.
What are employers’ requirements to partner (e.g integration capabilities, clinical and economic evidence, usability, data privacy & security, etc)?
What are the pros and cons of targeting employers directly vs. going through resellers/broker platforms
What are the implications of choosing the employer route to market? (e.g impact on the evidence generation process, pricing, marketing, organizational structure, etc)
In a B2B2C model, how do we ensure patient activation and long-term engagement?